Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02105116 · ClinicalTrials.gov registry record · NA
AML Therapy With Irradiated Allogeneic Cells
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02105116: Clinical Trial NA study, sponsored by Rutgers, The State University of New Jersey.
NCT02105116 is a NA study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02105116, a NA study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR after the standard induction chemotherapy are eligible for the experimental therapy (irradiated haploidentical cells).
Primary Outcome
Patients will be observed for incidence of adverse events related to experimental therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Of the 6 patients enrolled, all were ineligible to enter the experimental treatment phase of the study because of failure to reach complete remission. None of the enrolled patients received experimental therapy (allogeneic donor lymphocyte therapy). The one death occurred while receiving standard
Interventions
- OTHER laboratory biomarker analysis
- DRUG G-CSF
- DRUG fludarabine phosphate
- DRUG cytarabine
- BIOLOGICAL donor lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12-16 |
| Phase | NA |
Why NCT02105116 stopped before completion
NCT02105116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02105116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02105116 about?
NCT02105116 is a clinical study titled "AML Therapy With Irradiated Allogeneic Cells". This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from ...
What is the current status of trial NCT02105116?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2014-02. Estimated completion is 2015-12-16.
What interventions are being tested in trial NCT02105116?
The interventions under investigation include: laboratory biomarker analysis (OTHER), G-CSF (DRUG), fludarabine phosphate (DRUG), cytarabine (DRUG), donor lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02105116?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02105116's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia